Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.40 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | CPN1 | P15169 | 2/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.33 |
| ▸ | APLNR | P35414 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1049250 | 0.98 | SLC6A1 (0.39) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1047563 | 0.98 | SLC6A1 (0.39) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL27157670 | 0.91 | SSTR4 (0.37) | SLC6A1SLC6A11SLC6A13SSTR4EPHX1 | |
| SCHEMBL8613519 | 0.91 | SSTR4 (0.37) | SLC6A1SLC6A11SLC6A13SSTR4EPHX1 | |
| Hydrochloric Acid SCHEMBL29262906 | 0.89 | SSTR4 (0.36) | SLC6A1SLC6A11SLC6A13SSTR4EPHX1 | |
| Tert-Butyl Formate SCHEMBL27655209 | 0.88 | TDP1 (0.36) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Tert-Butyl Formate SCHEMBL27655208 | 0.88 | TDP1 (0.36) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Tert-Butyl Formate SCHEMBL27655210 | 0.88 | TDP1 (0.36) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL27655272 | 0.85 | SLC6A1 (0.37) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL27675037 | 0.85 | SLC6A1 (0.37) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113840820-B | Phthalazinone compounds and uses thereof | ST制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| US-20220235011-A1 | PHTHALAZINONE COMPOUNDS AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2022-07-28 | — | — | US | disclosed |
| EP-3978480-A1 | PHTHALAZINONE COMPOUNDS AND USE THEREOF | ST Pharm Co., Ltd. (KR) | 2022-04-06 | — | — | EP | disclosed |
| CN-113840820-A | Phthalazinone compounds and uses thereof | ST制药株式会社 | 2021-12-24 | — | — | CN | disclosed |
| WO-2020242245-A1 | PHTHALAZINONE COMPOUNDS AND USE THEREOF | 에스티팜 주식회사 | 2020-12-03 | — | — | WO | disclosed |
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-16 | — | — | US | disclosed |
| WO-2018021977-A1 | GLYCINE METABOLISM MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-01 | — | — | WO | disclosed |
| US-7868036-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-01-11 | — | — | US | disclosed |
| US-20080058320-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-03-06 | — | — | US | disclosed |
| EP-1725530-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005090304-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235011-A1 | PHTHALAZINONE COMPOUNDS AND USE THEREOF | SIRT6, SIRT1, SIRT2 | SLC6A1 1307/4885SLC6A11 1701/4885TSHR 3428/4885 |
| US-20080058320-A1 | Organic Compounds | REN, AGTR1, ADH1C | SLC6A1 971/4885SLC6A11 1283/4885TSHR 817/4885 |
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | NR1H2, NR1H3, NR1H4 | SLC6A1 2690/4885SLC6A11 2068/4885TSHR 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.